ArticleOncology research2025

Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study.

Keiko Yanagihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.